COZAAR

Compare COZAAR  to:
Compare
Compare

Generic Name for COZAAR

Losartan potassium 25mg, 50mg, 100mg; tabs.

Legal Classification:

Rx

Pharmacological Class for COZAAR

Angiotensin II receptor blocker.

Manufacturer of COZAAR

Merck & Co., Inc.

Indications for COZAAR

Hypertension (HTN). To reduce stroke risk in hypertensive patients with left ventricular hypertrophy (LVH); this benefit may not apply to black patients.

Adult dose for COZAAR

Hypovolemia or hepatic insufficiency: initially 25mg once daily. HTN: initially 50mg once daily; range 25–100mg/day; max 100mg/day in 1 or 2 divided doses. HTN with LVH: initially 50mg once daily; then add hydrochlorothiazide (HCTZ) 12.5mg/day and/or increase losartan to 100mg/day, then may increase HCTZ to 25mg/day.

Children's dosing for COZAAR

<6 years or CrCl <30mL/min: not recommended. ≥6 years: initially 0.7mg/kg (max 50mg) once daily; usual max 1.4mg/kg (100mg) once daily.

Contraindications for COZAAR

Pregnancy (Cat.D in 2nd and 3rd trimesters).

Precautions for COZAAR

Correct salt/volume depletion before starting therapy, or reduce initial dose. Renal or hepatic impairment. Severe CHF. Renal artery stenosis. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended.

Interactions for COZAAR

Antihypertensive effect reduced by NSAIDs. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Monitor lithium.

Adverse Reactions for COZAAR

Dizziness, insomnia, muscle cramps, leg pain, hyperkalemia, angioedema, rhabdomyolysis (rare).

How is COZAAR supplied?

Tabs 25mg—90, 1000, 10000
50mg—30, 90, 1000, 10000
100mg—30, 90, 1000, 5000

Related Disease:

Hypertension

Related Resources

The Medicines Company expands Cleviprex recall

March 18, 2010

The FDA and The Medicines Company have notified healthcare professionals of an additional recall of 4 lots of Cleviprex (clevidipine butyrate injectable emulsion).

FDA warns of reduced Plavix efficacy in poor metabolizers

March 15, 2010

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.

Benicar gains expanded indication for treatment of hypertension in children

February 11, 2010

The FDA has approved Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) for the treatment of hypertension in children and adolescents 6-16 years of age.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cleviprex injection recalled due to presence of particulate matter

December 17, 2009

The FDA and The Medicines Company have notified healthcare professionals of a voluntary nationwide recall of 11 lots of Cleviprex (clevidipine butyrate) injection emulsion due to the presence of visible particulate matter observed in some vials.